Recombinant Mouse Antibody (4C2) is capable of binding to S protein. This antibody could block virus entry in vitro with high efficacy.
Figure 1 Interference of the spike/hCD26 interaction by the antibodies.
hCD26 was transiently expressed in BHK21 cells and tested by flow cytometry for MERS-RBD binding with or without the antibodies. Left to right: no antibody, with 2H8 (a non-neutralizing antibody targeting MERS-RBD), with 2E6, with 4C2.
Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J.,... & Zhang, B. (2015). A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.Cell research, 25(11), 1237.
Figure 2 In vitro neutralization tests using the pseudotyped and the live viruses.
The non-neutralizing antibody 2H8 or an irrelevant antibody L2 was used as the negative controls. Neutralization of the pseudoviruses by the antibodies (D). Neutralization of the live viruses by the antibodies (E).
Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J.,... & Zhang, B. (2015). A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.Cell research, 25(11), 1237.
Figure 3 Humanized 4C2 (4C2h) sustains similar neutralizing activity and biochemical characters to 4C2.
(A) SPR analysis of the MERS-RBD binding to 4C2h. The kinetic profile is shown. (B) Flow cytometric assay showing the blocking by 4C2h of the binding between MERS-RBD and hCD26 on the cell surface. (C, D) In vitro neutralization tests of 4C2h using the pseudotyped (C) and the live (D) viruses. The non-neutralizing antibody 2H8 or an irrelevant antibody L2 was used as the negative controls. The data are from four independent experiments, and mean ± SD is presented. (E, F) Protective efficacies of 4C2h in vivo. Ad5-hCD26-transduced BALB/c mice were treated intravenously with a single dose of antibody one day before (E) or after (F) the MERS-CoV challenge. Virus titers in the lungs were measured at 3 and 5 dpi and are expressed as PFUs per gram of lung tissue.
Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J.,... & Zhang, B. (2015). A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein.Cell research, 25(11), 1237.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
PABL-325 | Mouse Anti-MERS-CoV S Recombinant Antibody (PABL-325) | Neut, FACS, ELISA, FuncS | Mouse IgG2a |
PABL-326 | Human Anti-MERS-CoV S Recombinant Antibody (clone m336) | WB, Neut, FuncS | Human IgG1 |
PABL-327 | Human Anti-MERS-CoV S Recombinant Antibody (clone MERS-27) | Neut, FuncS | Human IgG |
PABC-274 | Recombinant Human Anti-MERS-CoV S Antibody (MCA1) | ELISA, Neut, FuncS | Human IgG |
HPAB-0310-YJ | Human Anti-MERS-CoV S Recombinant Antibody (HPAB-0310-YJ) | ELISA, Neut, FuncS | Human IgG1, κ |
There are currently no Customer reviews or questions for PABL-324. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.